MEDIWOUND LTD (MDWD) Fundamental Analysis & Valuation

NASDAQ:MDWD • IL0011316309

Current stock price

16.63 USD
+0.13 (+0.79%)
At close:
16.5 USD
-0.13 (-0.78%)
After Hours:

This MDWD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MDWD Profitability Analysis

1.1 Basic Checks

  • In the past year MDWD has reported negative net income.
  • In the past year MDWD has reported a negative cash flow from operations.
  • In the past 5 years MDWD always reported negative net income.
  • In the past 5 years MDWD always reported negative operating cash flow.
MDWD Yearly Net Income VS EBIT VS OCF VS FCFMDWD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10M -20M -30M

1.2 Ratios

  • MDWD has a Return On Assets (-27.68%) which is in line with its industry peers.
  • With a Return On Equity value of -54.73%, MDWD perfoms like the industry average, outperforming 49.21% of the companies in the same industry.
Industry RankSector Rank
ROA -27.68%
ROE -54.73%
ROIC N/A
ROA(3y)-26.3%
ROA(5y)-37.35%
ROE(3y)-57.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDWD Yearly ROA, ROE, ROICMDWD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200 -200

1.3 Margins

  • MDWD has a Gross Margin of 19.19%. This is comparable to the rest of the industry: MDWD outperforms 51.31% of its industry peers.
  • MDWD's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MDWD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-27.18%
GM growth 5Y-11.17%
MDWD Yearly Profit, Operating, Gross MarginsMDWD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MDWD Health Analysis

2.1 Basic Checks

  • MDWD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MDWD has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, MDWD has more shares outstanding
  • MDWD has a worse debt/assets ratio than last year.
MDWD Yearly Shares OutstandingMDWD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
MDWD Yearly Total Debt VS Total AssetsMDWD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • MDWD has an Altman-Z score of -1.02. This is a bad value and indicates that MDWD is not financially healthy and even has some risk of bankruptcy.
  • MDWD's Altman-Z score of -1.02 is in line compared to the rest of the industry. MDWD outperforms 43.46% of its industry peers.
  • MDWD has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
  • MDWD has a Debt to Equity ratio (0.19) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z -1.02
ROIC/WACCN/A
WACC8.37%
MDWD Yearly LT Debt VS Equity VS FCFMDWD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • MDWD has a Current Ratio of 2.33. This indicates that MDWD is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of MDWD (2.33) is comparable to the rest of the industry.
  • MDWD has a Quick Ratio of 2.17. This indicates that MDWD is financially healthy and has no problem in meeting its short term obligations.
  • MDWD has a Quick ratio of 2.17. This is comparable to the rest of the industry: MDWD outperforms 45.55% of its industry peers.
Industry RankSector Rank
Current Ratio 2.33
Quick Ratio 2.17
MDWD Yearly Current Assets VS Current LiabilitesMDWD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MDWD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 31.60% over the past year.
  • MDWD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.14%.
  • MDWD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.86% yearly.
EPS 1Y (TTM)31.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.56%
Revenue 1Y (TTM)-16.14%
Revenue growth 3Y-13.82%
Revenue growth 5Y-4.86%
Sales Q2Q%-68.03%

3.2 Future

  • MDWD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.70% yearly.
  • The Revenue is expected to grow by 53.62% on average over the next years. This is a very strong growth
EPS Next Y-33.65%
EPS Next 2Y0.42%
EPS Next 3Y11.76%
EPS Next 5Y26.7%
Revenue Next Year16.75%
Revenue Next 2Y25.57%
Revenue Next 3Y36.2%
Revenue Next 5Y53.62%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MDWD Yearly Revenue VS EstimatesMDWD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
MDWD Yearly EPS VS EstimatesMDWD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. MDWD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MDWD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDWD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDWD Price Earnings VS Forward Price EarningsMDWD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDWD Per share dataMDWD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.42%
EPS Next 3Y11.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDWD Dividend Analysis

5.1 Amount

  • No dividends for MDWD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDWD Fundamentals: All Metrics, Ratios and Statistics

MEDIWOUND LTD

NASDAQ:MDWD (5/1/2026, 8:00:01 PM)

After market: 16.5 -0.13 (-0.78%)

16.63

+0.13 (+0.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)03-05
Earnings (Next)05-19
Inst Owners50.17%
Inst Owner Change-0.04%
Ins Owners2.16%
Ins Owner Change0%
Market Cap213.70M
Revenue(TTM)16.96M
Net Income(TTM)-23.88M
Analysts83.33
Price Target30.4 (82.8%)
Short Float %16.47%
Short Ratio18.47
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)42.05%
Min EPS beat(2)13.08%
Max EPS beat(2)71.01%
EPS beat(4)3
Avg EPS beat(4)15.7%
Min EPS beat(4)-110.94%
Max EPS beat(4)89.63%
EPS beat(8)4
Avg EPS beat(8)-27.99%
EPS beat(12)7
Avg EPS beat(12)-6.34%
EPS beat(16)7
Avg EPS beat(16)-14.39%
Revenue beat(2)0
Avg Revenue beat(2)-44.98%
Min Revenue beat(2)-70.05%
Max Revenue beat(2)-19.91%
Revenue beat(4)0
Avg Revenue beat(4)-29.2%
Min Revenue beat(4)-70.05%
Max Revenue beat(4)-1.43%
Revenue beat(8)1
Avg Revenue beat(8)-17.97%
Revenue beat(12)2
Avg Revenue beat(12)-13.54%
Revenue beat(16)5
Avg Revenue beat(16)-4.93%
PT rev (1m)-5.4%
PT rev (3m)-5.4%
EPS NQ rev (1m)0.25%
EPS NQ rev (3m)-7.1%
EPS NY rev (1m)-13.78%
EPS NY rev (3m)-11.18%
Revenue NQ rev (1m)-13.33%
Revenue NQ rev (3m)-49.31%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)-10.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.6
P/FCF N/A
P/OCF N/A
P/B 4.9
P/tB 4.9
EV/EBITDA N/A
EPS(TTM)-2.1
EYN/A
EPS(NY)-2.81
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.25
OCFYN/A
SpS1.32
BVpS3.4
TBVpS3.39
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -27.68%
ROE -54.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.19%
FCFM N/A
ROA(3y)-26.3%
ROA(5y)-37.35%
ROE(3y)-57.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-27.18%
GM growth 5Y-11.17%
F-Score4
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 295.97%
Cap/Sales 32.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.33
Quick Ratio 2.17
Altman-Z -1.02
F-Score4
WACC8.37%
ROIC/WACCN/A
Cap/Depr(3y)405.02%
Cap/Depr(5y)259.73%
Cap/Sales(3y)32.69%
Cap/Sales(5y)20.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.56%
EPS Next Y-33.65%
EPS Next 2Y0.42%
EPS Next 3Y11.76%
EPS Next 5Y26.7%
Revenue 1Y (TTM)-16.14%
Revenue growth 3Y-13.82%
Revenue growth 5Y-4.86%
Sales Q2Q%-68.03%
Revenue Next Year16.75%
Revenue Next 2Y25.57%
Revenue Next 3Y36.2%
Revenue Next 5Y53.62%
EBIT growth 1Y-30.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.14%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.33%
OCF growth 3YN/A
OCF growth 5YN/A

MEDIWOUND LTD / MDWD Fundamental Analysis FAQ

What is the fundamental rating for MDWD stock?

ChartMill assigns a fundamental rating of 2 / 10 to MDWD.


Can you provide the valuation status for MEDIWOUND LTD?

ChartMill assigns a valuation rating of 0 / 10 to MEDIWOUND LTD (MDWD). This can be considered as Overvalued.


Can you provide the profitability details for MEDIWOUND LTD?

MEDIWOUND LTD (MDWD) has a profitability rating of 1 / 10.


What is the expected EPS growth for MEDIWOUND LTD (MDWD) stock?

The Earnings per Share (EPS) of MEDIWOUND LTD (MDWD) is expected to decline by -33.65% in the next year.